New Insights on Saporin Resistance to Chemical Derivatization with Heterobifunctional Reagents

Biomedicines. 2023 Apr 19;11(4):1214. doi: 10.3390/biomedicines11041214.

Abstract

Saporin is a type 1 ribosome-inactivating protein widely used as toxic payload in the construction of targeted toxins, chimeric molecules formed by a toxic portion linked to a carrier moiety. Among the most used carriers, there are large molecules (mainly antibodies) and small molecules (such as neurotransmitters, growth factors and peptides). Some saporin-containing targeted toxins have been used for the experimental treatment of several diseases, giving very promising results. In this context, one of the reasons for the successful use of saporin lies in its resistance to proteolytic enzymes and to conjugation procedures. In this paper, we evaluated the influence of derivatization on saporin using three heterobifunctional reagents, namely 2-iminothiolane (2-IT), N-succinimidyl 3-(2-pyridyldithio)propionate (SPDP) and 4-succinimidyloxycarbonyl-α-methyl-α-[2-pyridyldithio]toluene (SMPT). In order to obtain the highest number of inserted -SH groups with the lowest reduction of saporin biological activities, we assessed the residual ability of saporin to inhibit protein synthesis, to depurinate DNA and to induce cytotoxicity after derivatization. Our results demonstrate that saporin maintains an excellent resistance to derivatization processes, especially with SPDP, and permit us to define reaction conditions, in which saporin biological properties may not be altered. Therefore, these findings provide useful information for the construction of saporin-based targeted toxins, especially with small carriers.

Keywords: cancer therapy; chemical derivatization; conjugates; heterobifunctional reagents; immunotoxins; plant toxins; rRNA N-glycosylases; ribosome-inactivating proteins; saporin; targeted toxins.

Grants and funding

This work was supported by funds for selected research topics from the Alma Mater Studiorum, University of Bologna, by the Pallotti Legacies for Cancer Research.